FY2026 EPS Estimates for Amgen Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2026 earnings per share (EPS) estimate for Amgen from $21.75 to $21.85, maintaining a "Neutral" rating with a price target of $305.00.
• For the latest quarter, Amgen reported $6.02 EPS, exceeding expectations, and achieved a net margin of 18.96% with revenues of $9.18 billion, up 9.4% year-over-year.
• Amgen recently declared a quarterly dividend of $2.38 per share, yielding approximately 3.2% annually with a payout ratio of 77.84%.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Research analysts at Cantor Fitzgerald upped their FY2026 EPS estimates for shares of Amgen in a research report issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now expects that the medical research company will post earnings per share of $21.85 for the year, up from their previous estimate of $21.75. Cantor Fitzgerald has a "Neutral" rating and a $305.00 price target on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. During the same quarter last year, the firm earned $4.97 EPS. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

Several other equities analysts have also recently commented on the stock. Weiss Ratings raised shares of Amgen from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday. Bank of America lifted their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an "underperform" rating in a report on Friday, September 26th. Raymond James Financial began coverage on shares of Amgen in a report on Wednesday, September 3rd. They issued a "market perform" rating on the stock. Morgan Stanley lifted their price target on shares of Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Citigroup lifted their price target on shares of Amgen from $310.00 to $315.00 and gave the stock a "neutral" rating in a report on Wednesday, September 24th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $309.42.

Amgen Price Performance

Amgen stock opened at $295.43 on Friday. Amgen has a 52 week low of $253.30 and a 52 week high of $335.88. The company's 50 day moving average price is $286.91 and its two-hundred day moving average price is $287.79. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The stock has a market cap of $159.05 billion, a P/E ratio of 24.16, a P/E/G ratio of 2.56 and a beta of 0.49.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date was Friday, August 22nd. Amgen's payout ratio is 77.84%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Wealth Preservation Advisors LLC purchased a new position in Amgen in the first quarter worth $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen in the second quarter worth $27,000. First Pacific Financial grew its position in Amgen by 304.5% in the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after acquiring an additional 67 shares in the last quarter. CBIZ Investment Advisory Services LLC grew its position in Amgen by 1,214.3% in the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock worth $29,000 after acquiring an additional 85 shares in the last quarter. Finally, Evelyn Partners Investment Management LLP purchased a new position in Amgen in the second quarter worth $32,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.